Physicians' Academy for Cardiovascular Education

Lp(a)

Follow news, literature, education and expert opinions on the emerging role of Lp(a) as riks factor and therapeutic target in cardiovascular disease

Targeting Lp(a): therapeutic insights and novel developments

10' education - Oct. 12, 2022 - Prof. Erik Stroes, MD, PhD

Lp(a) as independent causal risk factor: why should we focus on testing?

10' education - Oct. 11, 2022 - Prof. Florian Kronenberg, MD, PhD

The clinical challenge: a patient with multiple risk factors

10' education - Oct. 7, 2022 - Prof. Erik Stroes, MD, PhD

Targeting Lp(a) in CV risk reduction: where are we now?

10' education - Oct. 5, 2022 - Pia Kamstrup, MD, PhD

No role of Lp(a) in thrombosis

3' education - June 16, 2022 - Prof. Alberico Catapano, PhD

How to overcome the excess ASCVD risk conferred by Lp(a)?

3' education - June 1, 2022 - Prof. Alberico Catapano, PhD

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD

Working towards eradication of CV risk

10' education - Dec. 15, 2021 - Prof. Erik Stroes, MD, PhD

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Online CME

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD - Online CME

Why focus on Lp(a)?

10' education - Sep. 13, 2021 - Prof. Naveed Sattar, MD, PhD - Online CME

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD - Online CME

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD - Online CME

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD

Icosapent ethyl has minimal effect on 7 atherosclerotic biomarkers

Literature - Nov. 14, 2022 - Ridker PM, et al. - Circulation. 2022

In a REDUCE-IT substudy, icosapent ethyl had little to no effect on biomarkers associated with atherosclerotic disease, such as IL-1β, IL-6, oxidized LDL-c, and Lp(a). However, mineral oil increased these levels.

siRNA therapy reduces Lp(a) in patients with established ASCVD

News - Nov. 9, 2022

AHA 2022 The phase 2 OCEAN(a)-DOSE study showed that olpasiran dosed 75 mg or higher every 12 weeks reduces Lp(a) by >95% in patients with elevated Lp(a) and established ASCVD.

Targeting Lp(a): therapeutic insights and novel developments

10' education - Oct. 12, 2022 - Prof. Erik Stroes, MD, PhD
The importance of measuring Lp(a) has been established. The next big question is: will we be able to attenuate Lp(a)-associated risk?

The importance of measuring Lp(a) has been established. The next big question is: will we be able to attenuate Lp(a)-associated risk?

Lp(a) as independent causal risk factor: why should we focus on testing?

10' education - Oct. 11, 2022 - Prof. Florian Kronenberg, MD, PhD
Prof. Kronenberg talks about the importance of measuring Lp(a) levels. He also discusses the challenges in determining Lp(a), the rationale for risk thresholds and whether genetic testing is necessary.

Prof. Kronenberg talks about the importance of measuring Lp(a) levels. He also discusses the challenges in determining Lp(a), the rationale for risk thresholds and whether genetic testing is necessary.

The clinical challenge: a patient with multiple risk factors

10' education - Oct. 7, 2022 - Prof. Erik Stroes, MD, PhD
How can we make the best choices for optimal, affordable and sustainable care for patients with high CV risk due to multiple risk factors? Prof. Stroes illustrates the challenge of choosing.

How can we make the best choices for optimal, affordable and sustainable care for patients with high CV risk due to multiple risk factors? Prof. Stroes illustrates the challenge of choosing.

Targeting Lp(a) in CV risk reduction: where are we now?

10' education - Oct. 5, 2022 - Pia Kamstrup, MD, PhD
Pia Kamstrup gives an overview of studies on Lp(a)-associated risk. She shows that elevated Lp(a) levels are associated with CVD and aortic valve stenosis, and that Lp(a)-associated risk is independent of other risk factors.

Pia Kamstrup gives an overview of studies on Lp(a)-associated risk. She shows that elevated Lp(a) levels are associated with CVD and aortic valve stenosis, and that Lp(a)-associated risk is independent of other risk factors.

EAS consensus statement on Lp(a) in ASCVD and aortic stenosis

News - Sep. 12, 2022

The Journal of the European Heart Journal has published the 2022 European Atherosclerosis Society consensus statement on Lp(a) in atherosclerotic cardiovascular disease and aortic stenosis.

No role of Lp(a) in thrombosis

3' education - June 16, 2022 - Prof. Alberico Catapano, PhD

EAS 2022 "According to [these] data, there is no reason why you should give aspirin to an individual with high Lp(a)," says prof. Catapano. He recapitulates the findings of a study by Olmastroni and colleagues.

How to overcome the excess ASCVD risk conferred by Lp(a)?

3' education - June 1, 2022 - Prof. Alberico Catapano, PhD
It is recommended that risk factors, such as LDL-c, should be controlled in patients with high Lp(a) levels. Prof. Catapano briefly summarizes the findings of a study on this topic that was presented at EAS 2022.

EAS 2022 It is recommended that risk factors, such as LDL-c, should be controlled in patients with high Lp(a) levels. Prof. Catapano briefly summarizes the findings of a study on this topic that was presented at EAS 2022.

How much LDL-c lowering is needed to overcome the increased ASCVD risk caused by high Lp(a)?

News - May 25, 2022

EAS 2022 Thus far there is no effective therapy to reduce Lp(a) levels. Risk factor modification is recommended for persons with high Lp(a), but how much LDL-c lowering is needed to overcome the increased ASCVD risk caused by high Lp(a)?

Lp(a) is not associated with thrombotic events

News - May 25, 2022

EAS 2022 A study found that Lp(a) is not associated with VTE and the increased risk of MI caused by high Lp(a) levels is unlikely to be decreased by antiplatelet or antithrombin therapy.

Lp(a) level increases during childhood

Literature - May 2, 2022 - De Boer LM, et al. - Atherosclerosis. 2022

Lp(a) levels are thought to stay stable over time, at least in adults. As several lipid values change during childhood, Lp(a) values were measured in a large cohort of children. The result: Lp(a) levels increased with age.